These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36544993)

  • 21. Prevalence of Carbapenem-Resistant
    Zeng L; Deng Q; Zeng T; Liu Y; Zhang J; Cao X
    Microb Drug Resist; 2020 May; 26(5):483-491. PubMed ID: 31682180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outbreak of KPC-3 Producing Carbapenem-Resistant Klebsiella pneumoniae in a US Pediatric Hospital.
    Stillwell T; Green M; Barbadora K; Ferrelli JG; Roberts TL; Weissman SJ; Nowalk A
    J Pediatric Infect Dis Soc; 2015 Dec; 4(4):330-8. PubMed ID: 26582872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surveillance of carbapenem-resistant
    Zhou Y; Zhao Z; Zeng L; Peng J; Zhou S; Min L; Ke J; Liu J
    J Med Microbiol; 2022 Jan; 71(1):. PubMed ID: 35060850
    [No Abstract]   [Full Text] [Related]  

  • 24. Molecular Mechanisms Mediating Ceftazidime/Avibactam Resistance Amongst Carbapenem-Resistant
    El-Kady RAE; Elbaiomy MA; Elnagar RM
    Infect Drug Resist; 2022; 15():5929-5940. PubMed ID: 36247738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic Resistance, Molecular Characteristics and Risk Factors of Carbapenem-Resistant
    Zhu J; Chen Y; Yang X
    Infect Drug Resist; 2022; 15():6671-6680. PubMed ID: 36411757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections.
    Dubrovskaya Y; Chen TY; Scipione MR; Esaian D; Phillips MS; Papadopoulos J; Mehta SA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5394-7. PubMed ID: 23959321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of NDM-5-Producing Carbapenem-Resistant
    Li Q; Zhu J; Kang J; Song Y; Yin D; Guo Q; Song J; Zhang Y; Wang S; Duan J
    Infect Drug Resist; 2020; 13():3075-3089. PubMed ID: 32943891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Epidemiology, Microbial Virulence, and Resistance of Carbapenem-Resistant
    Peng C; Feng DH; Zhan Y; Wang Q; Chen DQ; Xu Z; Yang L
    Microb Drug Resist; 2022 Jun; 28(6):698-709. PubMed ID: 35639427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant
    Zhou J; Yang J; Hu F; Gao K; Sun J; Yang J
    Infect Drug Resist; 2020; 13():2571-2578. PubMed ID: 32801794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outbreak of Multidrug-Resistant OXA-232-Producing ST15
    Jia H; Zhang Y; Ye J; Xu W; Xu Y; Zeng W; Liao W; Chen T; Cao J; Wu Q; Zhou T
    Infect Drug Resist; 2021; 14():4395-4407. PubMed ID: 34729016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Factors for Subsequential Carbapenem-Resistant
    Chen X; Liu Q; Liu WE; Yan Q
    Infect Drug Resist; 2020; 13():1299-1305. PubMed ID: 32440167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Epidemiology of Carbapenem-Resistant
    Wang S; Dong H; Wang M; Ma W; Cheng Y; Zhou J; Cheng Y; Xu H; Yu X
    Can J Infect Dis Med Microbiol; 2022; 2022():2615753. PubMed ID: 36510603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant
    Fang J; Li H; Zhang M; Shi G; Liu M; Wang Y; Bian X
    Front Pharmacol; 2021; 12():780940. PubMed ID: 34955849
    [No Abstract]   [Full Text] [Related]  

  • 34. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dissemination of Klebsiella pneumoniae ST11 isolates with carbapenem resistance in integrated and emergency intensive care units in a Chinese tertiary hospital.
    Yu F; Hu L; Zhong Q; Hang Y; Liu Y; Hu X; Ding H; Chen Y; Xu X; Fang X; Yu F
    J Med Microbiol; 2019 Jun; 68(6):882-889. PubMed ID: 31050634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of Non-Carbapenemase-Producing Carbapenem-Resistant
    Lee YQ; Sri La Sri Ponnampalavanar S; Chong CW; Karunakaran R; Vellasamy KM; Abdul Jabar K; Kong ZX; Lau MY; Teh CSJ
    Antibiotics (Basel); 2022 Nov; 11(11):. PubMed ID: 36421313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determining the susceptibility of carbapenem resistant Klebsiella pneumoniae and Escherichia coli strains against common disinfectants at a tertiary hospital in China.
    Chen Y; Liao K; Huang Y; Guo P; Huang H; Wu Z; Liu M
    BMC Infect Dis; 2020 Jan; 20(1):88. PubMed ID: 32000698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Klebsiella pneumoniae Infections in the Intensive Care Unit: Risk Factors Related to Carbapenem Resistance and Patient Mortality].
    Büyüktuna SA; Hasbek M; Çelik C; Ünlüsavuran M; Avcı O; Baltacı S; Fırtına Topcu K; Elaldı N
    Mikrobiyol Bul; 2020 Jul; 54(3):378-391. PubMed ID: 32755515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of fosfomycin resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae.
    Liu P; Chen S; Wu ZY; Qi M; Li XY; Liu CX
    J Glob Antimicrob Resist; 2020 Sep; 22():238-243. PubMed ID: 32061879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective investigation of carbapenem-resistant Klebsiella pneumonia transmission among the staff, environment and patients in five major intensive care units, Beijing.
    Yan Z; Zhou Y; Du M; Bai Y; Liu B; Gong M; Song H; Tong Y; Liu Y
    J Hosp Infect; 2019 Feb; 101(2):150-157. PubMed ID: 30529506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.